There are currently 118 clinical trials in Eugene, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Research Institute, Willamette Valley Cancer Institute and Research Center, University of Oregon and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
NCT05226507
Recruiting
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Register for Updates
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191
Recruiting
The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Williamette Cancer Center, Eugene, Oregon
Conditions: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Register for Updates
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Recruiting
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Oncology Associates of Oregon, PC, Eugene, Oregon
Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Register for Updates
Open-Label Extension Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension
NCT05968430
Recruiting
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Willamette Valley Clinical Studies, Eugene, Oregon
Conditions: Hypertension
Register for Updates
Phase III Study of AK112 for NSCLC Patients
NCT06396065
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Williamette Valley Cancer Institute and Research, Eugene, Oregon
Conditions: Non-Squamous Non-small Cell Lung Cancer
Register for Updates
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Willamette Valley Cancer Institute, Eugene, Oregon
Conditions: Low Grade Serous Ovarian Cancer
Register for Updates
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
NCT05852431
Recruiting
To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/07/2024
Locations: 89Bio Clinical Study Site, Eugene, Oregon
Conditions: Severe Hypertriglyceridemia
Register for Updates
RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055
Recruiting
To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use - and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Pacific Sports and Spine, LLC, Eugene, Oregon
Conditions: Pain
Register for Updates
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
NCT04192591
Recruiting
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Gender:
All
Ages:
45 years and above
Trial Updated:
06/06/2024
Locations: Pacific Sports and Spine, LLC, Eugene, Oregon
Conditions: Lumbar Spinal Stenosis
Register for Updates
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154
Recruiting
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2024
Locations: Research Site, Eugene, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
Recruiting
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Lexicon Investigational Site (187), Eugene, Oregon
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
NCT04170283
Recruiting
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon
Conditions: B-cell Malignancies
Register for Updates